Latest Listings And Ipos News

Zip Co Limited has reported a near doubling in cash earnings for Q1 FY26, driven by robust transaction growth and improved operating leverage, particularly in the US market. The company also doubled its share buy-back program and raised its US transaction volume growth guidance.

Power Minerals Limited is set to list on the US OTCQB market following strong investor interest after acquiring the Gamma Heavy Rare Earths and Uranium Project in California, aiming to boost liquidity and visibility in the US capital markets.

Lincoln Minerals has appointed Chris Wilcox as CEO and Greg English as Chair, marking a strategic leadership overhaul aimed at driving exploration growth across its South Australian mineral assets.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

DGL Group Limited remains suspended from ASX trading following delays in lodging audited accounts and a concerning auditor disclaimer. Investors await clarity on the company’s financial health and path to reinstatement.

PWR Holdings has announced significant board changes following its AGM, with founder Kees Weel stepping down as Managing Director to become Chairman, alongside new appointments to key governance roles.

DGL Group Limited has reported a larger-than-expected FY25 net loss following an increased goodwill impairment and received a Disclaimer of Opinion from its auditor due to inventory and control issues during a major ERP system rollout.

Zoono Group Limited has responded to an ASX price query following a recent surge in its share price and trading volume, confirming no undisclosed information exists and attributing market activity to ongoing shelf-life extension trials across multiple continents.

Vectus Biosystems has requested an immediate suspension of its ASX-listed shares pending a significant announcement about a transaction involving a compound in its drug library.

WAM Income Maximiser Limited has launched a Share Purchase Plan offering eligible shareholders a discounted entry point to increase their holdings, aiming to raise up to $48.1 million to fuel portfolio growth and deliver steady dividends.

WAM Income Maximiser Limited is offering eligible shareholders the chance to buy up to $30,000 in shares at a discount, aiming to raise $48.1 million to fuel growth and support monthly dividends.

WAM Income Maximiser Limited has successfully completed an oversubscribed $120.2 million placement, reflecting robust investor confidence since its April 2025 IPO. The company also declared a fully franked dividend for October and provided guidance for upcoming months.